Targeting constitutively activated FMS-like tyrosine kinase 3 [(FLT3); FLT3-ITD] with tyrosine kinase inhibitor (TKI) in acute myeloid leukemia (AML) leads to clearance of blasts in the periphery but not in the bone marrow, suggesting a protective effect of the marrow niche on leukemic stem cells. In this study, we examined the effect of stromal niche cells on CD34 
Introduction
Acute myeloid leukemia (AML) is organized as a hierarchy resembling normal hematopoiesis with leukemic stem cells (LSC) responsible for producing the bulk of leukemic blasts and sustaining the disease by their ability to self-renew (1, 2) . Conventional chemotherapy induces high rates of remission but cures only a small percentage of patients with AML (3). The persistence of LSCs in the bone marrow after chemotherapy is thought to be responsible for the high rate of relapse (4, 5) . Therefore, new strategies to eradicate residual LSCs are urgently needed. Targeting key signaling pathways with small molecule inhibitors is one therapeutic approach currently being evaluated.
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase overexpressed on leukemic blasts in almost all cases of AML (6) . Activating mutations in the FLT3 gene in the form of internal tandem duplications (FLT3-ITD) can be identified in one third of AML patients and are associated with poor prognosis and increased relapse rates (7, 8) . These mutations induce constitutive tyrosine kinase activity in the absence of FLT3 ligand (FL) and confer growth factor independence, proliferation, and survival to myeloid cells in mouse models. Introduction of FLT3-ITD into murine bone marrow induces myeloproliferative disease, indicating the importance of FLT3 mutations in malignant transformation (9) (10) (11) . FLT3-ITD mutations were shown to be present in primitive human CD34 þ
CD38
À cells, showing that the mutation can occur within the hematopoietic stem cell compartment (12) . Moreover, detection of FLT3-ITD in the CD34 þ CD33 À stem/progenitor cell fraction in children with FLT3-ITD þ AML was associated with a particularly poor prognosis (13) . Thus, targeting FLT3-ITD may improve prognosis by enabling eradication of leukemic CD34 þ stem/ progenitor cells. Indeed, inhibition of constitutively active FLT3 has been shown to prolong survival in a mouse model of FLT3-ITD þ leukemia (14, 15) and several tyrosine kinase inhibitors (TKI) have entered clinical trials (16) (17) (18) . However, although inhibition of mutant FLT3 leads to clearance of leukemic blasts in the periphery, the bone marrow often remains unchanged and remissions are usually short-lived (17, 19) , raising the question whether a protective effect of the marrow niche on LSCs exists. The stem cell niche of the bone marrow provides a supportive microenvironment for normal hematopoietic stem cells (20, 21) and regulates the balance between self-renewal and differentiation in the stem cell pool (20) . Newer data suggest that LSCs are also protected by the stem cell niche and may even manipulate the microenvironment to their advantage (21, 22) . If so, the interaction between leukemic FLT3-ITD þ stem/progenitors and the niche may influence the efficacy of TKI on these cells. We addressed this question by investigating the effects of the TKIs SU5614 and sorafenib on leukemic CD34 þ stem/progenitor cells from AML patients with wild-type (FLT3-WT) or mutated (FLT3-ITD) FLT3 receptor in the presence or absence of niche cells. The murine embryonic stromal cell line EL08-1D2 was used as an in vitro model for the stem cell niche (23) .
Materials and Methods
Bone marrow samples Bone marrow samples were obtained from patients recruited to the German AMLSG trials between 2002 and 2010 (Table 1) . Written informed consent in accordance with the Declaration of Helsinki was obtained from all patients prior to bone marrow aspiration according to a protocol approved by the local Ethics Committee. All patients were newly diagnosed and untreated. Bone marrow samples In some experiments, CD34-enriched cells were labeled for 10 minutes at 37 C with 2 mmol/L of the fluorescent dye 5-(and 6-)carboxy-fluorescein succinimidyl ester (CFSE; Molecular Probes) in Iscove's modified Dulbecco's medium (GIBCO; Invitrogen), 1% fetal calf serum, and 10 mmol/L HEPES (Gibco) as described (25) . To determine the location of undivided cells for cell division tracking, a control culture was set up in the same manner but was additionally supplemented with colcemid (Karyomax; Gibco) as described (26) . Stromal cell lines FBMD-1 and EL08-1D2 were cultured as described (23) . The RS4;11 and MV4-11 human leukemia cell lines were obtained from and propagated as suggested by the German Collection of Microorganisms and Cell Cultures (DSMZ) and were authenticated by DSMZ by DNA typing and PCR analysis as well as cytogenetic testing. Cells used for all experiments were passaged for fewer than 6 months after receipt.
Culture of CD34
þ progenitor cells from primary AML samples CD34 þ progenitors from AML bone marrow samples were cultured in serum-free medium supplemented with 5 growth factors (5GF): kit ligand (KL), FL, thrombopoietin (TPO), interleukin (IL)-3, and Hyper-IL-6, a designer cytokine consisting of IL-6 and soluble IL-6 receptor (H-IL-6; a kind gift from S. Rose-John, Kiel, Germany; ref. 27 ). Cells were cultured in suspension or on confluent EL08-1D2 stromal cells and treated with SU5614, sorafenib, or dimethyl sulfoxide (DMSO) as indicated. Cells were maintained at 37 C in a humidified atmosphere with 5% CO 2 . After 4 days, cells were harvested and assayed for short-and long-term hematopoietic activity.
Analysis of apoptosis in CD34
þ cells
CD34
þ bone marrow cells were cultured in serum-free medium with 5GF and DMSO or SU5614. After the indicated time, cells were harvested and stained for Annexin V and propidium iodide (PI) as described by the manufacturer (ApoTest-FITC; Becton Dickinson). Cells were washed in PBS supplemented with 1% bovine serum albumin, resuspended in PBS buffer containing RNAse (100 mg/mL) and PI (50 mg/mL), followed by flow cytometry done on an Epics XL cytometer (Beckman Coulter). Acquired data were analyzed using FlowJo Software (version 8.7.3 for Macintosh).
Hematopoietic progenitor cell clonogenic assays
Mature hematopoietic progenitors were assessed by colony formation before and after 4 days of 5GF-supplemented serumfree culture. A total of 1,000 to 5,000 input cell equivalents were plated in growth factor-supplemented methylcellulose (H4435; Stem Cell Technologies) and incubated at 37 C in a humidified atmosphere with 5% CO 2 . After 14 days, colony-forming units (CFU) were scored using standard criteria.
Immature hematopoietic stem/progenitors were determined after long-term culture on the FBMD-1 stromal cell line in the presence of TPO and FL as described (25) . After 6 weeks of culture, the entire culture was harvested by trypsin detachment and assayed for the presence of long-term, culturederived colony-forming cells (LTC-CFC) in methylcellulose.
PCR for FLT3
AML bone marrow samples were validated for the presence of FLT3-ITD by PCR after isolation of mononuclear cells, as well as after both CD34 enrichment and culture in methylcellulose. For PCR from hematopoietic colonies, single hematopoietic colonies were picked from methylcellulose. Total genomic DNA was isolated using the QiaAmp Micro Kit (Qiagen) and eluted into 30 mL TE (Tris-EDTA) buffer. Eight microliters of single colony-derived genomic DNA was amplified by FLT3-ITD PCR. Products were resolved on 2% agarose gels and visualized under UV light after ethidium bromide staining.
Western blot analysis
MV4-11 or RS4;11 cells or primary CD34 þ cells were starved overnight in suspension culture or on the stromal cell line EL08-1D2 at 37 C in 5% CO 2 . Cells were incubated with SU5614 (5 mmol/L), sorafenib (100 nmol/L), or DMSO at 37 C and 5% CO 2 for indicated time periods . Cells were placed in pre-chilled tubes containing ice-cold PBS with Na 2 VO 4 (1 mmol/L; Sigma) and washed once in cold PBS with Na 2 VO 4 . Cell lysis, SDS-PAGE, and immunoblotting were done as described (25) . Antibodies to FLT3 (S-18, sc-480; Santa Cruz Biotechnology) and pFLT3 (#3461; Cell Signaling Technologies), AKT1/pS473 and AKT1/pT308 AKT (all from Cell Signaling Technologies), ERK1 (K-23; Santa Cruz Biotechnology), pY204-ERK1 (E4; Santa Cruz Biotechnology), b-actin (Sigma), pY694STAT5 and STAT5 (Cell Signaling Technologies), and phosphotyrosine (4G10 and PY20; Transduction Laboratories) were used as described in manufacturers' instructions. Signals were visualized on Kodak films, using polyclonal secondary horseradish peroxidase-labeled antibodies (Pierce) and enhanced chemoluminescence (Pierce). Band intensities were determined using the ImageJ software package (NIH).
ELISA for FL
Levels of murine and human FL in stroma coculture were measured using species-specific Quantikine ELISA kits for murine (MFK00) and human FL (DFK00) following the manufacturer's instructions (R&D Systems).
Statistics
For analysis of functional assays of patient samples, we used nonparametric tests for both unpaired (between WT and ITD) and paired (within either WT or ITD) comparisons. For unpaired comparisons, we used the Mann-Whitney U test; for paired samples, the Wilcoxon matched pairs signed-rank test was used. To test for possible differences between groups in other experiments, we used the paired t test. Statistical testing was done using InStat software (GraphPad Software).
Results

Characteristics of AML patient samples
The characteristics of AML bone marrow samples used in this study are summarized in Table 1 . A total of 21 AML samples harboring the FLT3-ITD mutation were analyzed and compared with 13 AML samples without the mutation (FLT3-WT). The majority of samples (23 of 34) had normal cytogenetics. With the exception of sample 2, which additionally harbored an MLL-PTD mutation, and samples 10 to 12 and 20, 21, 27, which were NPM mutated, none of the other molecular abnormalities routinely screened for were detected in the remaining 27 AML samples. Primary FLT3-ITD þ AML samples showed variable expression of CD34 (Table 1 ), CD38 and FLT3 receptor (CD135), as shown in Figure 1 . Enrichment for CD34 by magnetic bead isolation was successful in all samples.
Cell death induction in primary leukemic
The effect of TKI on growth factor-stimulated leukemic CD34
þ cells was first studied using the TKI SU5614, which has been shown to effectively inhibit FLT3-ITD and activated FLT3-WT kinase (28) . We confirmed the selective inhibitory effect of SU5614 in human leukemia cell lines containing either the wild-type FLT3 receptor (RS4;11) or FLT3-ITD (MV4-11) mutation ( Fig. 2A) 1D2 stroma prevented SU5614-induced apoptosis. This was not observed for MV4-11 cells (Fig. 2C ).
was suppressed by treatment with SU5614 ( Fig. 3A) , confirming inhibition of the target mutation in primary leukemic cells. Coculture on EL08-1D2 stroma partially overcame inhibition of phosphorylation by SU5614 ( Fig. 3A and B) . We therefore looked downstream from FLT3 to investigate whether signaling differences occurred during coculture on stroma. Of particular interest was STAT5, whose phosphorylation and subsequent activation is a hallmark of the oncogenic FLT3-ITD pathway (29, 30) . In MV4-11 cells, SU5614 inhibited phosphorylation of STAT5 in suspension and when cocultured with EL08-1D2 ( Fig. 3C and D) . Phosphorylation of both T308 Research.
on January 13, 2018. © 2011 American Association for Cancer cancerres.aacrjournals.org Downloaded from and S473 AKT and ERK was also inhibited by SU5614 (Fig. 3D) . In EL08-1D2 stromal cells analyzed as a control, both AKT phosphorylation sites were found to be constitutively phosphorylated and were not inhibited by SU5614 (Fig. 3D) .
In untreated AML patient samples, activated STAT5 was more readily detectable in CD34 þ FLT3-ITD þ cells (7 of 7 samples) than FLT3-WT cells (4 of 7 samples) and was not inhibited by SU5614 ( Fig. 3C and E) . In CD34 þ FLT3-ITD þ cells cultured in suspension, SU5614 inhibited phosphorylation of AKT (at T308) and ERK whereas phosphorylation of AKT at S473 was not affected (Supplementary Fig. S3 ). Coculture on EL08-1D2 cells did not influence signaling pathways down- Fig. 3E and Supplementary Fig. S3 ). Thus, while SU5614 inhibits FLT3 and T308AKT and ERK pathways, STAT5 and S473AKT phosphorylation seem to be uncoupled from FLT3-ITD activation status in primary leukemic CD34 þ cells.
SU5614 increases the fraction of undivided leukemic CD34 þ cells
Analysis of primary CD34
þ AML cells revealed the majority to be in G 0 -G 1 phase of the cell cycle after 4 days of growth factor stimulation (data not shown), precluding detection of an inhibitory effect of SU5614 on cell cycle. Therefore, although one mechanism of action for TKI is cell-cycle arrest, this effect is not readily detectable in primary CD34 þ cells. We reasoned that an analysis of cell division might provide a better discrimination of TKI effect. Cell division was indeed detectable by CFSE staining, with the majority of samples dividing once during the 4-day period. FLT3-ITD þ AML samples contained a significantly higher proportion of cells that did not divide during the 4-day culture than did FLT3-WT samples ( Supplementary Fig. S1 ). Treatment with SU5614 significantly increased the fraction of nondividing cells in both FLT3-ITD þ and FLT3-WT samples. This effect was almost completely reversed by coculture with EL08-1D2 stroma for CD34 þ FLT3-WT cells but not for CD34 Supplementary Fig. S1C ).
TKI eradicates short-term committed leukemic progenitor cells, but stromal contact counteracts this effect Next, we investigated hematopoietic activity of primary hematopoiesis (31) and have confirmed by our CFSE experiments for leukemic progenitors. All of the 5 FLT3-WT AML samples studied yielded colony growth at day 0 (i.e. input) and after the 4-day culture. However, 3 of the 12 FLT3-ITD þ AML samples (samples 3, 6, and 7) used for progenitor cell assays did not form colonies either at day 0 or after 4 days of in vitro culture (Table 1 and Supplementary Table S1 Fig. S2 ).
Inhibition of activated FLT3 by SU5614 does not eradicate primitive leukemic progenitors in FLT3-ITD þ or FLT3-WT AML To address the question whether inhibition of activated FLT3 can effectively target the most primitive leukemic progenitor cell population, we conducted long-term in vitro culture experiments, resulting in a functional readout for the early progenitor cell fraction (31) . As shown in Figure  4B and Supplementary Table S2, the number of more primitive LTC-CFCs was very heterogeneous within untreated FLt3-ITD þ and FLT3-WT samples and not statistically different between the two groups. Exposure to SU5614 over 4 days in suspension culture did not eliminate primitive leukemic progenitors, either in FLT3-ITD þ or FLT3-WT samples ( Fig. 4B and C, Supplementary Table S 2).
Early FLT3-ITD þ stem/progenitor cells protected by stromal niche cells are amplified by treatment with SU5614 To determine the contribution of stromal support on maintenance of leukemic LTC-CFCs, we assessed the effect of SU5614 on primitive CD34 þ progenitors cultured on EL08-1D2 stroma. We have previously shown that this murine embryonic stromal cell line supports long-term production of both mature and immature human hematopoietic progenitors and can therefore mimic the stem cell niche in vitro (23, 32) . Culture on EL08-1D2 effectively prevented loss of FLT3-ITD þ LTC-CFCs during the 4-day in vitro culture (Fig. 4B ). In contrast, there was no significant difference in the number of LTC-CFCs between suspension cultures and stromal supported cultures for FLT3-WT samples (Fig. 4B) . Absolute colony numbers from all bone marrow samples are summarized in Supplementary Table S2 . An unexpected finding was the expansion of LTC-CFCs in the context of stromal support and treatment with SU5614 in FLT3-ITD þ AML samples. As depicted in Figure 4B , LTC-CFCs were expanded 3.5-fold compared with day 0 in the presence of EL08-1D2 and SU5614. Compared with progenitors cultured on stroma without TKI, expansion of LTC-CFCs was 2.6-fold in the presence of SU5614. The increase in LTC-CFCs on stroma in the presence of SU5614 was observed for 8 of 9 FLT3-ITD þ patient samples, ruling out the possibility of singular outliers distorting the overall results. To better assess the contribution of EL08-1D2 stroma to stimulation of leukemic progenitors, a ratio between colony numbers for SU5614-treated versus DMSO-treated cultures was formed. As shown in Figure 4C , stromal support led to significant stimulation of colony growth in FLT3-ITD þ progenitors whereas this was not the case for FLT3-WT progenitor cells, indicating that stromal support is necessary for expansion of FLT3-ITD þ progenitors.
Expanded LTC-CFCs are of leukemic origin Because primitive AML progenitors are thought to have a growth advantage over their normal counterparts (33), we sought to ascertain whether expanded LTC-CFCs from FLT3-ITD þ samples were of leukemic origin or whether stromal contact conferred a survival advantage to healthy progenitor cells. PCR for FLT3-ITD in individual hematopoietic colonies from methylcellulose confirmed the presence of the FLT3 mutation in LTC-CFCs from all patient samples (Supplementary Fig. S4 ), indicating persistence of early leukemic progenitors.
Confirmatory studies with sorafenib
To confirm the general applicability of our findings, we repeated key experiments with a second TKI, sorafenib. This compound is a more selective and potent inhibitor of FLT3 than SU5614 and is currently widely used in the clinic (34) (35) (36) . As shown in Figure 5A , sorafenib effectively inhibited activated FLT3 in WT as well as FLT3-ITD þ AML. Inhibition of FLT3 phosphorylation by sorafenib was not influenced by stromal contact. As with SU5614, STAT5 signaling downstream of FLT3-ITD was not inhibited by sorafenib (Fig. 5B) , confirming uncoupling of FLT3-ITD and STAT5 in primary CD34
Colony-forming assays revealed that similar to SU5614, treatment with sorafenib did not eliminate short-or longterm leukemic progenitors (Fig. 5C ). Coculture with EL08-1D8 stromal cells again abolished the inhibitory effect of sorafenib, although expansion of progenitor cells was not statistically significant. Analysis of colonies by PCR again confirmed that a substantial number of colonies recovered from short-and long-term cultures contained the FLT3-ITD mutation despite treatment with sorafenib ( Supplementary Fig. S4E ).
Discussion
Despite entry of FLT3 inhibitors into clinical trials for FLT3-ITD þ AML, it has so far not been established whether inhibition of aberrant FLT3 signaling can actually eradicate the earliest stem/progenitor cells responsible for propagating the disease. We showed, using the FLT3 inhibitors SU5614 and sorafenib as proof of concept, in primary bone marrow samples from patients with newly diagnosed FLT3-ITD STAT5 by FLT3 has been shown to be dependent on intracellular localization of the receptor (30) , thus restricted to mutated FLT3 and not found in FLT3-WT signaling. In addition, FLT3-ITD itself has recently been shown to be differentially phosphorylated on different tyrosine residues in a compartment-dependent manner (30) . In this context, our results suggest that inhibition of mutated FLT3 by TKI in primary patient samples may take place mainly at the plasma membrane, allowing intracellular activation of STAT5 to persist. Our data extend findings previously obtained using leukemic cell lines with acquired resistance to TKI showing continued STAT5 activation in resistant cells (43, 44) . Prolonged exposure of leukemic cell lines or AML blasts to TKI opts for cells that are FLT3 independent, leading to pharmacologic resistance (35, 43, 44) . However, our results suggest that at least primitive CD34 þ FLT3-ITD þ progenitors are insensitive to TKI from the onset of treatment. The inability of TKI to sustain suppression of leukemic blasts may therefore be due not only to outgrowth of resistant blasts but also to the fact that the more primitive leukemic stem/progenitors maintaining the disease persist despite treatment with TKI. 
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